Profile
Jonathan G.
Drachman is a former Chairman & Chief Executive Officer of Aquinox Pharmaceuticals, Inc. He also served as the Chief Executive Officer of Neoleukin Therapeutics, Inc. Additionally, he held the position of President, Chief Executive Officer, CFO & Director at Neoleukin Therapeutics, Inc. from 2018 to 2023.
Dr. Drachman was the Medical Director-Umbilical Cord Blood Program at Bloodworks Northwest.
He served as an Independent Director at Calithera Biosciences, Inc. from 2013 to 2022.
Furthermore, he was an Independent Director at Harpoon Therapeutics, Inc. from 2018 to 2024.
Prior to that, Dr. Drachman was the Chief Medical Officer, EVP-Research & Development at Seagen Inc. from 2004 to 2018.
He also worked as a Clinical Professor-Medicine at the University of Washington from 1998 to 2004.
Dr. Drachman completed his undergraduate studies at Harvard University and obtained his doctorate degree from Harvard Medical School.
Former positions of Jonathan Drachman
| Companies | Position | End |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | Director/Board Member | 2024-03-10 |
| NEUROGENE INC. | Chief Executive Officer | 2023-03-30 |
| CALITHERA BIOSCIENCES, INC. | Director/Board Member | 2022-05-31 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 2018-05-16 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | 2003-12-31 |
Training of Jonathan Drachman
| Harvard University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CALITHERA BIOSCIENCES, INC. | Health Technology |
| HARPOON THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Bloodworks Northwest
 Bloodworks Northwest Medical/Nursing ServicesHealth Services Bloodworks Northwest is a non-profit company that encourages people to donate blood, time, or money to save lives. The company is based in Seattle, WA. The company's mission is to make an impact by collecting blood donations. | Health Services |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Neoleukin Therapeutics, Inc. /old/
 Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical firm utilizing sophisticated computational methods. develop and designs de novo protein therapeutics. The company was is headquartered in Seattle, WA. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Jonathan Drachman
